Repatha Cuts Death Risk by 20% for High-Risk Adults Without Prior Heart Attack

Amgen announced new findings from a Phase 3 trial showing that Repatha, its PCSK9 inhibitor treatment, reduced the risk of death in high-risk adults without a prior heart attack or stroke by 20%. The results were presented at the European Society of Cardiology Congress 2026 and published in Circulation. In a study of over 12,000 high-risk patients, Repatha helped lower the risk of dying from all causes, including cardiovascular events.

The reduction in deaths began to appear after approximately 1.5 years of treatment and continued through a median follow-up of 4.6 years. According to Amgen, Repatha may extend life by helping patients avoid serious health decline that can follow major cardiovascular events, contributing to fewer deaths overall.

Additional VESALIUS-CV analyses showed that Repatha reduced the risk of first, subsequent and total CV events. The benefits were consistent across key patient subgroups, adding to the growing body of evidence supporting the importance of earlier LDL-C lowering with Repatha in high-risk patients.